06.01.2015 Views

2011 ASH Program Book - American Society of Hypertension

2011 ASH Program Book - American Society of Hypertension

2011 ASH Program Book - American Society of Hypertension

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

Monday Morning Afternoon MAY 21 23<br />

Posters<br />

PO-336:<br />

PO-337:<br />

PO-338:<br />

PO-339:<br />

Resolution <strong>of</strong> <strong>Hypertension</strong> after Adjustable Gastric<br />

Banding – 1 Year Interim Results <strong>of</strong> the LAP-BAND<br />

AP® EXperience (APEX) Study<br />

John Dixon, 1 Michael Oefelein, 2 Ted Okerson†. 2<br />

1 Monash University, Melbourne, AU; 2 Allergan, Inc,<br />

Irvine, CA, US.<br />

Initial Aliskiren/HCTZ Combination Therapy<br />

Lowers BP in Obese Patients with Stage 2<br />

<strong>Hypertension</strong> and Type 2 Diabetes<br />

Raymond R. Townsend, 1 Alan Forker, 2 Thomas<br />

Severin, 3 Cheraz Cherif Papst, 3 Anthony Yadao. 4<br />

1 University <strong>of</strong> Pennsylvania Medical Center,<br />

Philadelphia, PA, US; 2 St Luke’s Lipid and Diabetes<br />

Research Center, Kansas City, MO, US; 3 Novartis<br />

Pharma AG, Basel, CH; 4 Novartis Pharmaceuticals<br />

Corporation, East Hanover, NJ, US.<br />

Aliskiren/HCTZ Inhibits RAAS Activity in Obese<br />

and Non-Obese Patients with Stage 2 <strong>Hypertension</strong><br />

and Type 2 Diabetes<br />

Raymond R. Townsend, 1 Alan Forker, 2 Thomas<br />

Severin, 3 Cheraz Cherif Papst, 3 Anthony Yadao. 4<br />

1 University <strong>of</strong> Pennsylvania Medical Center,<br />

Philadelphia, PA, US; 2 St Luke’s Lipid and Diabetes<br />

Research Center, Kansas City, MO, US; 3 Novartis<br />

Pharma AG, Basel, CH; 4 Novartis Pharmaceuticals<br />

Corporation, East Hanover, NJ, US.<br />

Aliskiren/Amlodipine Combination Lowers BP in<br />

Obese and Non-Obese Patients with Moderate-to-<br />

Severe <strong>Hypertension</strong><br />

Rudiger C. Braun‐Dullaeus, 1 Sergey B. Shustov, 2<br />

Carmen Alvarez, 3 Gregorio G. Rogelio, 4 Cheraz Cherif<br />

Papst, 5 Jack Zhang†. 6 1 Otto-von-Guericke University,<br />

Magdeburg, DE; 2 State Educational Institution <strong>of</strong><br />

High Pr<strong>of</strong>essional Education, St Petersburg, RU; 3 ABS<br />

Centelles, Barcelona, ES; 4 St Luke’s Medical Center,<br />

Quezon, PH; 5 Novartis Pharma AG, Basel, CH;<br />

6 Novartis Pharmaceuticals Corporation, East Hanover,<br />

NJ, US.<br />

Patient-Provider-Healthcare System<br />

Issues<br />

PO-340:<br />

PO-341:<br />

Clinical Inertia in <strong>Hypertension</strong>: Identifying<br />

Barriers to Improve Quality<br />

Bryan Batson, 1 JaNae Joyner, 2 Philip Mellen, 1 William<br />

Smith. 1 1 Hattiesburg Clinic, Hattiesburg, PA, US; 2 The<br />

Consortium for Southeastern <strong>Hypertension</strong> Control<br />

(COSEHC), Winston-Salem, NC, US.<br />

Renal Artery Stent Management: A Survey <strong>of</strong> Local<br />

Practice Patterns<br />

Frank K. Boateng, Daniel L. Landry, Barbara A. Greco.<br />

Baystate Medical Center, Springfield, MA, US.<br />

139

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!